MAP2K7 and Histiocytosis: The efficacy of these inhibitors as monotherapy has generally been limited (Brana et al. 2021, Eckstein et al. 2022, Sullivan et al. 2018), though notable exceptions include MEK inhibition for histiocytosis and low-grade serous ovarian cancer (LGSOC) (Diamond et al. 2019, Gershenson et al. 2022).